Skip to main content

6 Result(s)

within Article Remove this filter J-S Frenel Remove this filter

and

  1. No Access

    Article

    Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer

    Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody–drug conjugates (ADCs): Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), ...

    F. Poumeaud, M. Morisseau, L. Cabel, A. Gonçalves, C. Rivier… in British Journal of Cancer (2024)

  2. No Access

    Article

    Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation

    Efficacy of endocrine therapy in HR+/HER2− metastatic breast cancer could differ depending on the presence of BRCA1/2 germline mutation.

    J.-S. Frenel, A. Lusque, S. Delaloge, J.-M. Ferrero… in British Journal of Cancer (2023)

  3. No Access

    Article

    Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort

    Older cancer patients are underrepresented in clinical trials. We aimed to evaluate the enrollment of older women aged 70 years old (yo) or over with metastatic breast cancer (MBC) in clinical trials.

    M. Bringuier, M. Carton, C. Levy, A. Patsouris… in Breast Cancer Research and Treatment (2022)

  4. No Access

    Article

    Characteristics of IDH-mutant gliomas with non-canonical IDH mutation

    Approximately 10% of IDH-mutant gliomas harbour non-canonical IDH mutations (non-p.R132H IDH1 and IDH2 mutations).

    L. Poetsch, C. Bronnimann, H. Loiseau, J. S. Frénel… in Journal of Neuro-Oncology (2021)

  5. No Access

    Article

    Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience

    IDH1/2 mutations and 1p/19q codeletion occur frequently in anaplastic gliomas and are prognostic factors. We combined these two biomarkers to stratify patients treated for anaplastic oligodendroglioma (AO). 43...

    J. S. Frenel, C. Leux, D. Loussouarn, A.-G. Le Loupp… in Journal of Neuro-Oncology (2013)

  6. Article

    Open Access

    Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas

    Carcinoma cells lack syndecan-1 expression when they are transiting from an epithelial to a less-differentiated mesenchymal phenotype (epithelial–mesenchymal transition, EMT). Furthermore, a shift of syndecan-...

    D Loussouarn, L Campion, C Sagan, J-S Frenel, F Dravet… in British Journal of Cancer (2008)

    Download PDF (1209 KB) View Article